It often takes years to create a viable antibody test as accurate as PCR-based testing. But in less than six weeks, biotech companies—approached by the U.S. government through the White House-created public-private partnership—have already seen their efforts bear fruit. This is a tribute to the incredible creative potential of the biotech sector, but it also shows the power of free enterprise, unshackled by government bureaucracy. It took more than America’s best scientists to rise to the occasion: it took a regulatory regime to let them do so.
Read all of Chris von Csefalvay's City Journal essay here.